| Literature DB >> 28289525 |
Jamal N Khan1, Gerry P McCann1.
Abstract
Cardiovascular magnetic resonance (CMR) imaging uniquely characterizes myocardial and microvascular injury in acute myocardial infarction (AMI), providing powerful surrogate markers of outcomes. The last 10 years have seen an exponential increase in AMI studies utilizing CMR based endpoints. This article provides a contemporary, comprehensive review of the powerful role of CMR imaging in the assessment of outcomes in AMI. The theory, assessment techniques, chronology, importance in predicting left ventricular function and remodelling, and prognostic value of each CMR surrogate marker is described in detail. Major studies illustrating the importance of the markers are summarized, providing an up to date review of the literature base in CMR imaging in AMI.Entities:
Keywords: Cardiovascular magnetic resonance; Infarct; Left ventricular remodelling; Myocardial infarction; Prognosis
Year: 2017 PMID: 28289525 PMCID: PMC5329738 DOI: 10.4330/wjc.v9.i2.109
Source DB: PubMed Journal: World J Cardiol
Figure 1Cardiovascular magnetic resonance markers are ideal surrogate biomarkers for the assessment of revascularisation in acute myocardial infarction[2-4]. CMR: Cardiovascular magnetic resonance; AMI: Acute myocardial infarction; LGE: Late gadolinium enhancement.
Cardiovascular magnetic resonance studies illustrating the prognostic importance of left ventricular ejection fraction in acute myocardial infarction
| El Aidi et al[ | 2014 | 25497 | N/A | Meta analysis of prognostic value of CMR surrogate markers. LVEF was only IP for MACE (HR 1.05 per -5%) | N/A |
| Husser et al[ | 2012 | 304 | 7 d | LVEF was IP for MACE (HR 0.95 for each +1% LVEF) | 140 wk |
| Eitel et al[ | 2011 | 208 | 3 d | LVEF was IP for MACE (HR 0.95 for each +1% LVEF) | 18.5 mo |
| Amabile et al[ | 2010 | 114 | 6 d | LVEF was IP for MACE (HR 0.96 for each +1% LVEF) | 12 mo |
| de Waha et al[ | 2010 | 438 | 3 d | LVEF was IP for MACE (OR 1.63) and all-cause mortality (OR 2.51) | 19 mo |
| Cochet et al[ | 2009 | 127 | 3-7 d | LVEF of < 40% was IP for MACE (OR 1.20) | 12 mo |
| Hombach et al[ | 2005 | 110 | 6 d | LVEF was IP for 9 mo MACE ( | 225 d |
CMR time: Mean/median time of CMR post acute STEMI; MACE: Major adverse cardiovascular events; IP: Independent predictor; LVEF: Left ventricular ejection fraction; CMR: Cardiovascular magnetic resonance; N/A: Not available.
Studies illustrating the prognostic importance of left ventricular volumes and adverse left ventricular remodelling in acute myocardial infarction
| Ahn et al[ | 2013 | 135 | Echo | Adverse LV remodelling (> 20% inc. LVEDV) at 6 mo was IP 3 yr MACE. MACE rate approximately 25% in patients with adverse LV remodelling | 981 d |
| Hombach et al[ | 2005 | 110 | CMR | Baseline LVEDV was IP for MACE ( | 225 d |
| St John Sutton et al[ | 2003 | 512 | Echo | Percentage change in LV area (surrogate for LV volume) between baseline echo and follow-up at 12 mo was IP for ventricular ectopy and VT | 24 mo |
| Bolognese et al[ | 2002 | 284 | Echo | Baseline LVESV was IP for cardiac death and MACE. Components of MACE higher in patients with adverse remodelling (> 20% inc. LVEDV: Mortality 14% | 5 yr |
| Otterstad et al[ | 2001 | 712 | Echo | Increase in LVESV between acute scan at 7 d and echo at 3 mo strongest IP for MACE | 24 mo |
| St John Sutton et al[ | 1994 | 512 | Echo | LV end-diastolic area (RR 1.1) and LV end-systolic area (RR 1.1) on baseline echo, and %-change in LV area at 12 mo echo (RR 1.55) were strongest IPs for MACE | 12 mo |
| White et al[ | 1987 | 605 | LV gram | LVESV of LV gram at 4 wk was strongest IP of long-term mortality ( | 78 mo |
MACE: Major adverse cardiovascular events; IP: Independent predictor; LVEDV: Left ventricular end-diastolic volume; LVESV: Left ventricular end-systolic volume; Modality: Modality of LV volume assessment (CMR: Cardiovascular MRI; Echo: Echocardiography; LV gram: LV contrast angiography).
Figure 2Cardiovascular magnetic resonance assessment of strain using tissue tagging. Cine SSFP images in end-diastole (A) and end-systole (C), with corresponding Spatial Modulation of Motion (SPAMM) tagged images (B and D). Grid lines (tags) are visible and contours drawn at 3 myocardial levels [green (epicardial), red (mid myocardial), yellow (endocardial)] allow tracking of myocardial motion and strain (circumferential), here using Harmonic Phase Analysis.
Studies illustrating the prognostic importance of left ventricular strain in acute myocardial infarction
| Ersbøll et al[ | 2014 | 1048 | TTE | (E-prime divided by peak early diastolic strain rate) strongest IP of MACE and death | 29 mo |
| Ersbøll et al[ | 2013 | 849 | TTE | GLS was IP of MACE | 30 mo |
| Hung et al[ | 2010 | 610 | TTE | GLS and strain-rate, and GCS and strain-rate IPs for MACE in model with WMS, LVEF | 25 mo |
| Antoni et al[ | 2010 | 659 | TTE | GLS (HR 1.2) was IP of mortality. LVEF, wall-motion score and Tissue Doppler mitral valve inflow not | 21 mo |
TTE: Transthoracic echocardiography; GLS: Global longitudinal strain; MACE: Major adverse cardiovascular events; IP: Independent predictor; HR: Hazard ratio; LVEF: Left ventricular ejection fraction.
Figure 3Mechanism of late gadolinium enhancement. Gadolinium is extracellular. A: In normal myocardium, gadolinium washes out approximately 10 min post administration and there is no late gadolinium enhancement (LGE); B: In acute infarct, gadolinium (yellow stars) enters ruptured cell membranes and causes LGE; C: In chronic infarct, LGE results from increased extracellular space due to fibrotic scar deposition.
Figure 4Late gadolinium enhancement of acute infarct. Infarct appears white (enhanced) in the inferior wall, with unaffected myocardium black (nulled). A: 2-chamber long-axis view; B: Short-axis view, mid ventricular level. The posteromedial papillary muscle is also infarcted in the short-axis view.
Temporal changes in cardiovascular magnetic resonance-derived infarct size in acute myocardial infarction
| Carrick et al[ | 2016 | 30 | 8 h → 3 d → 10 d → 7 mo | 26% | Automated | Significant decrease d3 to d10 (20% ± 13% to 14% ± 10% LV mass). No change at 7 mo |
| Dall’Armelina et al[ | 2011 | 30 | 2 d → 6 mo | 22% | > 2SD | IS reduced at times from 27% ± 15% LV mass 24 h post PPCI, to 21% ± 11% at 6 mo |
| Mather et al[ | 2011 | 48 | 2 d → 1 wk → 30 d → 3 mo | 37% | > 2SD | 27% IS drop between d2 and d7 post PPCI, no change at 3 mo |
| Ganame et al[ | 2011 | 58 | 3 d → 4 mo → 12 mo | 45% | Manual | 33% decrease IS d3 and 4 mo then no further decrease at 12 mo |
| Ibrahim et al[ | 2010 | 17 | 1 d → 1 wk → 1 mo → 6 mo | 37% | Manual | 34% reduction in IS from d2 to 1 wk, then no further change at 1 and 6 mo |
| Engblom et al[ | 2009 | 22 | 1 d → 1 wk → 12 mo | 40% | Automated | 28% reduction in IS between d1 and 1 wk |
| Ripa et al[ | 2007 | 58 | 2 d → 1 mo → 6 mo | 30% | Manual | 14% % reduction in IS from d2 to 1 mo |
| Hombach et al[ | 2005 | 110 | 6 d → 9 mo | 28% | Manual | 28% reduction in IS from d6 to 9 mo |
LGE method: SD: Standard deviations; Total LGE IS Overest: Relative overestimation of final IS (last timepoint) on acute CMR; CMR: Cardiovascular magnetic resonance; LGE: Late gadolinium enhancement; IS: Infarct size; PPCI: Primary percutaneous coronary intervention.
Cardiovascular magnetic resonance studies illustrating importance of segmental late gadolinium enhancement extent and functional recovery in acute myocardial infarction
| Khan et al[ | 2016 | FWHM | 50% SEE | SEE strong predictor or segmental functional improvement (AUC 0.840) and normalisation (AUC 0.887) | 2 d | 9 mo | |
| Wong et al[ | 2014 | 45 | FWHM | 50% SEE | Inverse relationship between TEE and likelihood of functional recovery on WMS at 24 wk (area under curve 0.68) | 8 d | 13 wk |
| Natale et al[ | 2011 | 46 | 2SD | 50% TEE | Inverse relationship TEE and likelihood of functional recovery on SWT (93% sens, 75% spec) | 5 d | 20 wk |
| Engblom et al[ | 2008 | 22 | Manual | 50% TEE | Inverse relationship between TEE and functional recovery on WMS | 7 d | 24 wk |
| Shapiro et al[ | 2007 | 17 | Manual | 50% SEE | Inverse relationship between TEE and likelihood of functional recovery on WMS at 26 wk. Odds-ratio of functional recovery 0.2 with each SEE quartile | 6 d | 26 wk |
| Kitagawa et al[ | 2007 | 18 | 2SD | 50% TEE | Inverse relationship between TEE and functional recovery. 31% segments > 50% TEE still improved | 5 d | 39 wk |
| Janssen et al[ | 2006 | 67 | Manual | 50% TEE | Inverse relationship between TEE and functional recovery on WMS at 12w (51%-75%: 39% segments improved, 76%+: 21% improved) | 4 d | 12 wk |
| Motoyasu et al[ | 2004 | 23 | 2SD | 50% TEE | Inverse relationship between SEE and functional recovery on SWT | 25 d | 24 wk |
| Beek et al[ | 2003 | 30 | 6SD | 50% SEE | Inverse relationship between SEE and functional recovery on WMS | 7 d | 13 wk |
WMS: Wall motion scoring; SWT: Systolic wall thickening; TEE: Transmural extent of enhancement; SEE: Segmental extent of enhancement; SD: Standard deviations.
Cardiovascular magnetic resonance studies illustrating importance of infarct size on left ventricular function and remodelling in acute myocardial infarction
| Ahn et al[ | 2013 | 135 | Manual | IS strongest IP of LVR in model with LVEF and MI location | 7 d | 6 mo (echocardiogram) |
| Husser et al[ | 2012 | 304 | > 2SD | IS IP of LVR in model incl. LVEF, IS, LV vols, MVO | 6 d | 189 d |
| Monmeneu et al[ | 2012 | 118 | > 2SD | No. segments > 50% transmurality IP for LVR | 6 d | 6 mo |
| Ezekowicz et al[ | 2010 | 64 | Manual | IS strongest IP of LVEF in model with MVO, troponins | 7 d | 3 mo |
| Ganame et al[ | 2009 | 98 | Manual | IS strongest IP of LVR (>> MVO, AAR, Troponin-I) | 2 d | 6 mo |
| Bodi et al[ | 2009 | 214 | > 2SD | Extent of transmural necrosis (no. segments > 50% TEE) strongest IP for LV recovery (+ > 5% LVEF) | 7 d | 6 mo |
| Wu et al[ | 2008 | 122 | Manual | IS extent only IP for LVEF and LVR | 2 d | 4 mo |
| Hombach et al[ | 2005 | 110 | Manual | IS extent IP of LVR in model with MVO, % transmurality | 6 d | 225 d |
IS: Infarct size; IP: Independent predictor; LVR: LV remodelling; LVEDVI: Left-ventricular end-diastolic volume index; LVEDVI: Left-ventricular end-systolic volume index; LVEF: Left ventricular ejection fraction; MVO: Microvascular obstruction; SD: Standard deviation.
Cardiovascular magnetic resonance studies illustrating the prognostic importance of infarct in acute myocardial infarction
| Husser et al[ | 2013 | 250 | > 2SD | Extent of transmural infarction (no. of segments > 50% transmurality) only IP for MACE at 6 mo | 7 d | 163 wk |
| Izquierdo et al[ | 2013 | 440 | > 2SD | IS was IP for AACEs (arrhythmic cardiac events: Sudden death, VT, VF, ICD shock) in model including LVEF, hypertension | 7 d | 123 wk |
| Eitel et al[ | 2011 | 208 | > 5SD | IS was IP of MACE at 19 mo in model including MVO, LVEF, MSI, Killip, TIMI post-PPCI | 3 d | 18.5 mo |
| Miszalski-Jamka et al[ | 2010 | 77 | Manual | LV transmurality index IP (HR 1.03) and IS (HR 1.03) IPs for MACE in a model containing RVEF and RV IS | “3-5 d” | 1150 d |
| Larose et al[ | 2010 | 103 | FWHM | IS strongest IP for MACE (HR 1.36) in model containing LVEF, CK. LGE > 23% had HR 6.1 for MACE | 4.5 h | 2 yr |
| Bodi et al[ | 2009 | 214 | > 2SD | Extent of transmural infarction (no. of segments > 50% transmurality) IP for MACE (HR 1.35 if > 5 segs) | 7 d | 553 d |
| Wu et al[ | 2008 | 122 | Manual | IS only IP of 2 yr MACE in model containing LVEF, LVESVI | 2 d | 538 d |
LGE: Late gadolinium enhancement; FWHM: Full-width half-maximum; SD: Standard deviations; MACE: Major adverse cardiovascular events; LVEF: Left ventricular ejection fraction; PPCI: Primary percutaneous coronary intervention; LGE method (LGE quantification method): SD: Standard deviations; FWHM: Full-width half-maximum.
Figure 5Early and late microvascular obstruction on cardiovascular magnetic resonance. A: Early gadolinium imaging at 1-min post contrast with hypoperfusion in anteroseptal, anterior and anterolateral segments, consistent with early MVO (E-MVO, *); B: Corresponding late gadolinium image showing transmural infarction with a hypointense late MVO core (L-MVO, **) co-localising with E-MVO. MVO: Microvascular obstruction.
Temporal changes in cardiovascular magnetic resonance late microvascular obstruction in acute myocardial infarction
| Carrick et al[ | 2016 | 30 | 8 h → 3 d → 10 d → 7 mo | Auto | L-MVO in 20%, peaked early at 8 h and stable at d3. Decreased by d10, absent at 7 mo |
| Mather et al[ | 2011 | 48 | 2 d → 1 wk → 30 d → 3 mo | > 2SD | L-MVO in 60%, peak at d2. Decrease at subsequent points. L-MVO absent at 3 mo |
| Ganame et al[ | 2011 | 58 | 3 d → 4 mo → 12 mo | Manual | L-MVO in 64%. L-MVO absent at 4 mo |
| Ripa et al[ | 2007 | 58 | 2 d → 6 mo | Manual | L-MVO in 42%. L-MVO absent at 6 mo |
| Hombach et al[ | 2005 | 110 | 6 d → 9 mo | Manual | 46% had L-MVO (2.8% LV mass, 16% of IS) on acute CMR. L-MVO absent at 6 mo |
MVO: Microvascular obstruction; LGE method: SD: Standard deviations; IS: Infarct size; LV: Left ventricle; CMR: Cardiovascular magnetic resonance.
Cardiovascular magnetic resonance studies illustrating the importance of late microvascular obstruction on left ventricular function and remodelling in acute myocardial infarction
| Kidambi et al[ | 2013 | 39 | > 2SD | L-MVO only IP of impaired infarct strain. Model with IS, TIMI flow, diabetes, transmurality | 3 d | 3 mo |
| Wong et al[ | 2012 | 40 | Manual | L-MVO extent only IP for LVEF at 3 mo in model including E-MVO, IS and myocardial blood flow on perfusion | 3 d | 3 mo |
| Ezekowitz et al[ | 2010 | 64 | Manual | L-MVO extent was IP of LVEF in model with IS and NT-proBNP | 7 d | 4 mo |
| Weir et al[ | 2010 | 100 | Manual | L-MVO extent was only IP of LVR in model with TIMI post PCI, E-MVO, IS | 4 d | 6 mo |
| Ganame et al[ | 2009 | 98 | Manual | L-MVO extent was IP of LVR in model with IS, troponin-I, TTR | 2 d | 6 mo |
| Nijveldt et al[ | 2008 | 60 | Manual | L-MVO presence strongest IP of LVEF change and LVR in model with TTR, IS, LVEF, E-MVO | 5 d | 4 mo |
| Hombach et al[ | 2005 | 110 | Manual | L-MVO extent IP for LVR in model with baseline IS, infarct transmurality | 6 d | 225 d |
MVO: Microvascular obstruction; IS: Infarct size; IP: Independent predictor; TTR: Time to revascularisation; LVR: Left ventricular remodelling; LVEF: Left ventricular ejection fraction; LVEDVI: Left-ventricular end diastolic volume index; LVESVI: Left-ventricular end systolic volume index.
Cardiovascular magnetic resonance studies illustrating the prognostic importance of late microvascular obstruction in acute myocardial infarction
| Regenfus et al[ | 2015 | 249 | Manual | L-MVO extent strongest IP for MACE in model including IS, LVEF, TIMI pre and post PPCI and no. diseased vessels | 3.7 d | 72 mo |
| Eitel et al[ | 2014 | 738 | > 5SD | Largest multicentre study of L-MVO in PPCI. L-MVO > 1.4% LVM and TIMI risk score only IPs of combined MACE. Adding L-MVO to model with clinical predictors, LVEF and IS increased c-statistic | 7 d | 6 mo |
| de Waha et al[ | 2012 | 438 | Manual | L-MVO extent IP for combined MACE in model including IS, LV volumes (only other IP was LVEF). L-MVO/IS strongest IP in model including L-MVO extent, LVEF, IS, LV volumes | 3 d | 19 mo |
| de Waha et al[ | 2010 | 438 | Manual | Presence and extent of L-MVO were strongest IPs for MACE and mortality in models with IS, LVEF, ST-res, TIMI-flow post PCI. E-MVO was not an IP | 3 d | 19 mo |
| Cochet et al[ | 2009 | 184 | Manual | L-MVO strongest IP for MACE, in models including GRACE score, IS, LVEF. L-MVO stronger IP than E-MVO (OR 8.7 | “3-7 d” | 12 mo |
| Bruder et al[ | 2008 | 143 | Manual | Only extent of L-MVO > 0.5% LV mass was IP for MACE; model included IS, LVEF, age, DM, sex | 4.5 d | 12 mo |
| Hombach et al[ | 2005 | 110 | Manual | L-MVO IP for MACE ( | 6 d | 268 d |
MVO: Microvascular obstruction; LVEF: Left ventricular ejection fraction; IS: Infarct size; PCI: Percutaneous coronary intervention; MACE: Major adverse cardiovascular events; IP: Independent predictor.
Figure 6Intramyocardial haemorrhage on cardiovascular magnetic resonance. A: T2-weighted spin-echo image with hypointensity corresponding with IMH within the hyperintense oedematous region in the inferior wall (red arrow); B: Corresponding LGE image showing co-localisation of IMH and L-MVO (yellow arrow). IMH: Intramyocardial haemorrhage; LGE: Late gadolinium enhancement; MVO: Microvascular obstruction.
Cardiovascular magnetic resonance studies illustrating the importance of intramyocardial haemorrhage on left ventricular function and remodelling in acute myocardial infarction
| Carrick et al[ | 2016 | 245 | T2* | IMH strongest IP for LVR. IMH associated with lower LVEF and greater volumes | 3 d | 7 mo |
| Kidambi et al[ | 2013 | 39 | T2w-TSE and T2* | IMH associated with attenuation of follow-up infarct strain | 3 d | 3 mo |
| Husser et al[ | 2012 | 304 | T2w-TSE | IMH strongest IP for LVR in model with LVEF, IS, LV vol, L-MVO | 6 d | 189 d |
| Mather et al[ | 2011 | 48 | T2w-TSE and T2* | IMH strongest IP of LVR in model with IS, LVEF, LVESV, E-MVO, MSI | 2 d | 3 mo |
| Beek et al[ | 2010 | 45 | T2w-TSE | IMH was a univariate predictor of LVEF. However no prognostic significance beyond baseline LVEF and MVO in predicting final LVEF | 5 d | 4 mo |
| Bekkers et al[ | 2010 | 90 | T2w-TSE | Acute MSI and LVEF increase at follow-up lowest if IMH present. But IMH no prognostic significance beyond MVO in predicting LVEF | 5 d | 103 d |
| O’Regan et al[ | 2010 | 50 | T2* | IMH presence univariate predictor of LVEF and LV volumes. However only IS independently predicted LVEF | 3 d | N/A |
| Ganame et al[ | 2009 | 98 | T2w-TSE | IMH extent strongest IP of LVR in model with IS, E-MVO, Troponin-I, AAR, TTR, IS | 2 d | 4 mo |
IS: Infarct size; IP: Independent predictor; LVR: Left ventricular remodelling; MVO: Microvascular obstruction; LVEF: Left ventricular ejection fraction; LVESVI: Left-ventricular end systolic volume index; T2w-TSE: T2-weighted turbo spin-echo; AAR: Area at risk; MSI: Myocardial salvage index; N/A: Not applicable.
Figure 7Alternative sequences to dark-blood T2-weighted turbo spin-echo for visualising oedema. Left: Inherent disadvantages of T2w-TSE[134,144-147]; Right: Sequences compared with T2w-TSE: (1)[145], (2)[141,142,144,148], (3)[149,150], (4)[144], (5)[151,152], (6)[153,154], (7)[155]. T2w-TSE: T2-weighted turbo spin-echo; DWI: Diffusion-weighted imaging; AAR: Area at risk.
Figure 8Calculation of salvaged myocardium. A: SSFP end-diastolic cine image; B: SSFP end-systolic cine image showing hypokinetic basal anterolateral segment (*); C: T2w-STIR image showing oedema (AAR) in anterolateral wall consistent with circumflex artery occlusion; D: Corresponding LGE image with near-transmural infarction; E: Calculation of salvaged myocardium in blue. SSFP: Steady-state free precession; T2w-STIR: T2-weighted short-tau inversion-recovery sequence; LGE: Late gadolinium enhancement.
Temporal changes in cardiovascular magnetic resonance-derived area at risk and myocardial salvage index in acute myocardial infarction
| Mather et al[ | 2011 | 48 | 2 d → 1 wk → 30 d → 3 mo | > 2SD STIR, > 2SD LGE | AAR reduction at successive timepoints, 1-3 mo (-75%). No change MSI at d2 or 1 wk as IS and AAR decreased proportionally |
| Dall’Armelina et al[ | 2011 | 30 | 2 d → 1 wk → 2 wk → 6 mo | > 2SD T2p-BB, > 2SD LGE | 100% had oedema at d2. AAR stable over 1st week (37% |
| Carlsson et al[ | 2009 | 16 | 1 d → 1 wk → 6 wk → 6 mo | Manual STIR, and LGE | AAR at all timepoints. AAR stable in 1st week, correlated with 1 wk SPECT. Decrease by 1 mo (10% LVM), nearly gone by 6 mo |
| Ripa et al[ | 2007 | 58 | 2 d → 1 mo → 6 mo | Manual STIR and LGE | All had oedema at d2. AAR decreased at all time points. No data on MSI in this study |
AAR: Area at risk; MSI: Myocardial salvage index; AAR, LGE method: SD: Standard deviations; STIR: T2-weighted short-tau inversion recovery imaging; T2p-SS-BB: T2-prepared single-shot bright-blood; 3T: 3.0 tesla field strength; IS: Infarct size.
Cardiovascular magnetic resonance studies showing the importance of myocardial salvage index on left ventricular function and remodelling in acute myocardial infarction
| Mather et al[ | 2011 | 48 | > 2SD STIR, > 2SD LGE | MSI was IP for LVR (OR 0.95) in model including LV volumes, LVEF, IS, IMH, MVO | 2 d | 3 mo |
| Monmeneu et al[ | 2012 | 118 | > 2SD STIR, > 2SD LGE | MSI univariate predictor of LVR and final LVEF. However not IP of LVR in model with LVESVI, IS, no. transmural segs | 6 d | 6 mo |
| Masci et al[ | 2011 | 260 | > 2SD STIR, > 5SD LGE | MSI strong univariate predictor of LVR and final LVEF. However not IP in model including IS, MVO | 1 wk | 4 mo |
| Masci et al[ | 2010 | 137 | > 2SD STIR, > 5SD LGE | MSI strongest IP for LVR However IS and MSI (r = -0.72) and IS and AAR (r = 0.85) correlated | 1 wk | 4 mo |
IS: Infarct size; IP: Independent predictor; LVR: Left ventricular remodelling; MVO: Microvascular obstruction; LVEF: Left ventricular ejection fraction; LVESVI: Left-ventricular end systolic volume index; STIR: T2-weighted short-tau inversion-recovery; LGE: Late gadolinium enhancement.
Cardiovascular magnetic resonance studies illustrating the prognostic importance of myocardial salvage index in acute myocardial infarction
| Eitel et al[ | 2011 | 208 | > 2SD -STIR, > 5SD LGE | MSI was only CMR-based IP of mortality in model with age, IS, MVO, LVEF, TIMI- post PPCI, diabetes, age (IS not IP). MSI not IP of MACE (only IS, LVEF, age were) | 3 d | 19 mo |
| Eitel et al[ | 2010 | 208 | > 2SD STIR, > 5SD LGE | MSI was only IP for MACE and mortality in model including LVEF, MVO, IS, ST-resolution and TIMI-grade post PCI | 3 d | 6 mo |
IS: Infarct size; PCI: Percutaneous coronary intervention; MACE: Major adverse cardiovascular events; IP: Independent predictor; MVO: Microvascular obstruction; LVEF: Left ventricular ejection fraction.
Cardiovascular magnetic resonance studies illustrating the prognostic importance of right ventricular infarction in acute myocardial infarction
| Jensen et al[ | 2010 | 50 | Manual | RVI only IP of MACE in model with age, sex, LVEF, LV IS | 3 d | 32 mo |
| Miszalski-Jamka et al[ | 2010 | 99 | Manual | RVEF (HR 1.46) and RVI extent (HR 1.50) IP for MACE | “3-5 d” | 1150 d |
| Grothoff et al[ | 2012 | 450 | Manual | RVI was IP of MACE (HR 6.70) | “1-4 d” | 20 mo |
MACE: Major adverse cardiovascular events; IP: Independent predictor; HR: Hazard ratio; RV: Right ventricle; LVEF: Left ventricular ejection fraction; LGE: Late gadolinium enhancement; IS: Infarct size; RVI: Right ventricular infarction.
Key studies illustrating the independent predictive value of cardiovascular magnetic resonance markers for left ventricular remodelling
| IS | Husser et al[ | 2012 | 304 | 2SD | IS extent IP for LVR in model with LVEF, IS, LV volumes, MVO | 6 d | 189 d |
| IS | Monmeneu et al[ | 2012 | 118 | 2SD | Number of segments > 50% transmurality IP for LVR | 6 d | 6 mo |
| IS | Wu et al[ | 2008 | 122 | Manual | IS extent at 2 d only IP for LVEF and LVR | 2 d | 4 mo |
| IS | Hombach et al[ | 2005 | 110 | Manual | IS extent at 6 d was an IP for LVR in model with MVO, % transmurality | 6 d | 225 d |
| L-MVO | Weir et al[ | 2010 | 100 | Manual | L-MVO extent was only IP of LVR in model with TIMI post PCI, E-MVO, IS | 4 d | 6 mo |
| L-MVO | Hombach et al[ | 2005 | 110 | Manual | L-MVO extent IP of LVR in model with baseline IS, infarct transmurality | 6 d | 225 d |
| IMH | Carrick et al[ | 2016 | 245 | T2* | IMH strongest IP of LVR in model with patient/angio characteristics, LVEDVI | 3 d | 7 mo |
| IMH | Husser et al[ | 2012 | 304 | T2w-TSE | IMH strongest IP for LVR in model with LVEF, IS, LV volumes, L-MVO | 6 d | 189 d |
| MSI | Monmeneu et al[ | 2012 | 118 | 2SD LGR/STIR | MSI univariate but not IP of LVR in model with IS, LVESVI, segments > 50% | 6 d | 6 mo |
| MSI | Masci et al[ | 2011 | 260 | 2SD STIR, 5SD LGE | MSI univariate predictor of LVR and final LVEF. However not IP of either | 1 wk | 4 mo |
| MSI | Masci et al[ | 2010 | 137 | > SD STIR, 5SD LGE | MSI strongest IP for LVR. However IS and MSI and IS and AAR correlated | 1 wk | 4 mo |
| T1 | Carrick et al[ | 2016 | 300 | T1 map, 2SD STIR, 5SD LGE | Infarct core native T1 inverse relationship with LVR (OR 0.91 per -10 ms T1) | 2 d | 6 mo |
Criteria: Individual studies with n ≥ 100 and follow-up CMR ≥ 3 mo post-PPCI. IS: Infarct size; L-MVO: Late microvascular obstruction; IMH: Intramyocardial haemorrhage; MSI: Myocardial salvage index; SD: Standard deviations; STIR: T2-weighted short-tau inversion recovery; LGE: Late gadolinium enhancement; IP: Independent predictor; LV: Left ventricular; LVEF: Left ventricular ejection fraction; AAR: Area at risk; LVEDVI: Left ventricular end-diastolic volume; CMR: Cardiovascular magnetic resonance.
Key studies illustrating the independent predictive value of cardiovascular magnetic resonance markers for prognosis
| IS | Husser et al[ | 2013 | 250 | > 2SD | Extent of transmural infarction was only IP for MACE | 7 d | 163 wk |
| IS | Izquierdo et al[ | 2013 | 440 | > 2SD | IS was IP for arrhythmic cardiac events in model including LVEF, hypertension | 7 d | 123 wk |
| IS | Eitel et al[ | 2011 | 208 | > 5SD | IS was IP of MACE in model with MVO, LVEF, MSI, Killip, TIMI flow post-PPCI | 3 d | 18.5 mo |
| IS | Larose et al[ | 2010 | 103 | FWHM | IS strongest IP for MACE in model with LVEF, CK. LGE > 23% for MACE | 4.5 h | 2 yr |
| IS | Bodi et al[ | 2009 | 214 | > 2SD | Extent of transmural infarction (no. of segments > 50% transmurality) IP for MACE | 7 d | 553 d |
| IS | Wu et al[ | 2008 | 122 | Manual | IS only IP of 2 yr MACE in model containing LVEF, LVESVI (HR 1.06) | 2 d | 538 d |
| L-MVO | Regenfus et al[ | 2015 | 249 | Manual | MVO extent strongest IP for MACE in model with IS, LVEF, TIMI and no. vessels | 3.7 d | 72 mo |
| L-MVO | Eitel et al[ | 2014 | 738 | > 5SD | L-MVO > 1.4% LVM IP of MACE in model with LVEDVI, LVEF, clinical markers | 7 d | 6 mo |
| L-MVO | de Waha et al[ | 2012 | 438 | Manual | L-MVO extent IP for MACE in model with IS, LV volumes. L-MVO/IS strongest IP | 3 d | 19 mo |
| L-MVO | de Waha et al[ | 2010 | 438 | Manual | L-MVO strongest IP of MACE/mortality in model with IS, LVEF, STR, TIMI post | 3 d | 19 mo |
| L-MVO | Cochet et al[ | 2009 | 184 | Manual | L-MVO strongest IP for MACE in model with GRACE, IS, LVEF. E-MVO weaker IP | “3-7 d” | 12 mo |
| L-MVO | Bruder et al[ | 2008 | 143 | Manual | L-MVO extent > 0.5% LV mass IP for MACE in model with IS, LVEF, age, DM, sex | 4.5 d | 12 mo |
| L-MVO | Hombach et al[ | 2005 | 110 | Manual | L-MVO IP for MACE ( | 6 d | 268 d |
| IMH | Carrick et al[ | 2016 | 245 | T2* | IMH strongest IP of CV death and HF. Multivariate model, L-MVO not predictor | 3 d | 830 d |
| IMH | Amabile et al[ | 2012 | 114 | T2w-TSE | IMH presence was strongest predictor of MACE in model with MVO, LVEF, STR | 4 d | 12 mo |
| IMH | Husser et al[ | 2012 | 304 | T2w-TSE | IMH IP for MACE in model with AAR, IS, L-MVO. T2w. No inc. value with LGE | 6 d | 140 wk |
| IMH | Eitel et al[ | 2011 | 346 | T2w-TSE | IMH IP of MACE in model with L-MVO. T2w inc. value with LGE and cine | 3 d | 6 mo |
| MSI | Eitel et al[ | 2011 | 208 | > 2SD/> 5SD | MSI only CMR IP of mortality in model with age, IS, MVO, LVEF, TIMI post, IS | 3 d | 19 mo |
| MSI | Eitel et al[ | 2010 | 208 | > 2SD/> 5SD | MSI only IP for MACE/mortality in model with LVEF, MVO, IS, STR, TIMI post | 3 d | 6 mo |
| T1 | Carrick et al[ | 2016 | 300 | T1 map, > 2SD STIR, > 5SD | Infarct core T1 inverse association with risk of mortality and heart failure hospitalisation, in model with LVEF, infarct T2, IMH. Similar prognostic as L-MVO | 2 d | 2.5 yr |
Criteria: Individual studies with n ≥ 100 and follow-up CMR ≥ 6 mo follow-up. IS: Infarct size; L-MVO: Late microvascular obstruction; IMH: Intramyocardial haemorrhage; MSI: Myocardial salvage index; SD: Standard deviations; STIR: T2-weighted short-tau inversion recovery; LGE: Late gadolinium enhancement; IP: Independent predictor; LV: Left ventricular; LVEF: Left ventricular ejection fraction; AAR: Area at risk; LVEDVI: Left ventricular end-diastolic volume; CK: Creatine kinase; T2w-TSE: T2-weighted turbo spin echo; MACE: Major adverse cardiovascular events; CV: Cardiovascular.